

Meet AZN management: ASCO 2020

Virtual breakout 4: *Calquence* and haematology

Michelle Werner, Andrew Mortlock

IR moderator: Henry Wheeler; supported by Aaron Kroft

1 June 2020

Webinar is being recorded




Forward-looking statements disclaimer

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective intellectual property (IP) protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK's exit from the EU; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; and the impact that the COVID-19 global pandemic may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.



Calquence

MCL¹ strong foundation, CLL² inflection point



Q1 2020 performance

- **Global \$88m; US \$86m**
- **US CLL**
Achieved ~1/4 of new patient starts.
~1/3 haematologists have tried and
~60% of demand from prescribers
new to *Calquence*
- **Global CLL**
Worldwide launch to continue in H2
2020 with more regulatory decisions

**ASCEND final results, CL-001 TN update,
and ISS-9 pooled safety at ASCO 2020**

Product sales at actual exchange rates.

1. Mantle cell lymphoma 2. Chronic lymphocytic leukaemia.

Source: AstraZeneca proprietary market research.



Haematology strategy

Launch, maximise, and accelerate the pipeline

Launch *Calquence*

MCL and CLL launches
around the globe

Maximise *Calquence*

Leadership in 1L CLL and
expand to other B-cell
malignancies

Accelerate pipeline

Data from early portfolio
highlights opportunities in
lymphoma, AML¹ and
myeloma

1. Acute myeloid leukaemia.




Novel inhibitors deliver strong anti-tumour effect

'What's next' pipeline molecules advancing through Phase II/I


AZD5991 (MCL1 inhibitor)

H929 *in vivo* efficacy



Innovative chemistry leading to novel macrocyclic design

AZD2811 (Aurora B inhibitor)




Novel nanoparticle with broad activity across AML sub-types

AZD4573 (CDK9 inhibitor)

New

In vivo efficacy in OCI-LY10



Distinct mechanism of targeting MCL1 via transcription inhibition

Source: Nature Communications, 2018, 9, 5341.


Source: Molecular Cancer Therapeutics, 2017, 16, 1031.

Source: poster 310/17, AACR 2018.



Phase I broadens haematology into new diseases

AZD0466 (Bcl2/xL inhibitor)




Nanomedicine technology improves therapeutic margin

Source: AstraZeneca, MedImmune and CRUK Cambridge Centre Symposium, 25-26 September 2017.

MEDI2228 (BCMA ADC)

New




Potential best-in-class ADC for treatment of myeloma

Source: Blood, 2019, 134 (Supplement_1): 1817.

Capivasertib (AKT¹ inhibitor)

New



New combinations in lymphoma


1. Protein kinase B.
Source: Blood, 2017, 130, 310.



Next wave of therapies


Innovative use of new modalities to deliver transformational change

ADCs and PROTACs



Targeted killing by targeting proteins immune to conventional approaches


Cell-based therapy



Harness the power of the immune system through 'living drugs'

Epigenetics

Example: AZD5153 (BRD4¹ inhibitor)



Selective targeting of the key resistance and survival pathways

Source: Front. Immunol., 2018; 9: 1821.

1. Bromodomain-containing protein 4.

Source: Molecular Cancer Therapeutics, 2016, 15, 2563.



Questions & Answers

To ask a question

Webinar

Click 'Raise Hand' (preferred):



or type your question into the Q&A box
(alternative)

Phone

*6 - Toggle mute/unmute

*9 - Raise hand



Use of AstraZeneca conference call, webcast and presentation slides

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca Materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine the AstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com

